Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention
In this economic evaluation, undergoing RRM appears cost-effective for women aged 30 to 55 years with a lifetime BC risk of 35% or higher. These results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers. Future studies evaluating the acceptability, uptake, and long-term outcomes of RRM among these women are warranted.
Authors
- Caitlin T. Fierheller (ORCID: https://orcid.org/0000-0001-9583-3061)
- Li Sun (ORCID: https://orcid.org/0000-0001-5569-7296)
- Ranjit Manchanda (ORCID: https://orcid.org/0000-0003-3381-5057)
- Jacqueline Sia (ORCID: https://orcid.org/0000-0002-1820-3194)
- Li Yang (ORCID: https://orcid.org/0000-0003-0640-2003)
- Stephen William Duffy (ORCID: https://orcid.org/0000-0003-4901-7922)
- Rosa Legood (ORCID: https://orcid.org/0000-0003-2761-5227)
- Ashwin Kalra (ORCID: https://orcid.org/0000-0002-5541-226X)
- Samuel Oxley (ORCID: https://orcid.org/0000-0003-1967-813X)
- Michail Sideris (ORCID: https://orcid.org/0000-0002-4199-6700)
- Adam R. Brentnall (ORCID: https://orcid.org/0000-0001-6327-4357)
- D. Gareth Evans (ORCID: https://orcid.org/0000-0002-8482-5784)
- Wei Xia (ORCID: https://orcid.org/0000-0001-5005-059X)
- Subhasheenee Ganesan
- Lea Mansour
Institutions
- Queen Mary University of London (GB)
- Peking University (CN)
- Barts Health NHS Trust (GB)
- Royal London Hospital (GB)
- St Mary's Hospital (GB)
- London School of Hygiene & Tropical Medicine (GB)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1001/jamaoncol.2025.2203
- Citations
- 3
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 5.45
Funders
- China Medical Board
- Barts Charity
- National Institute for Health and Care Research
- Rosetrees Trust
- Manchester Biomedical Research Centre